Join us for presentations using MRDR data and visit the Monash University booth - Blood 2026 Exhibition Hall Booth 012. We'd love to chat about the registry, answer any questions or just to come say hi!
.png)
Monday 19 October, 7.00am NZDT, Weta Uncorked, Auckland, New Zealand
New research using MRDR data explores toxicity-related treatment cessation and survival outcomes in newly diagnosed multiple myeloma patients.
Monday 19 October, 7.00am NZDT, Weta Uncorked, Auckland, New Zealand
MRDR report for belantamab mafodotin submitted to Pharmaceutical Benefits Advisory Committee (PBAC) public call.
Myeloma Australia Medical and Scientific Advisory Group (MSAG) Meeting - 1-2 May 2026
.png)
The MRDR has now surpassed an exciting milestone of over 9,000 registered patients.
MRDR report for teclistamab submitted to Pharmaceutical Benefits Advisory Committee (PBAC) public call
Three manuscripts using MRDR data have been published